---
trial_id: 323
discovery_date: 2022-04-02 17:30:16.047968
date: 2022-04-02 17:30:16.047968
title: "A 3-year, multi-center study to evaluate optical coherence tomography as an outcome measure in patients with multiple sclerosis"
summary: |
  <p>EudraCT Number: 2011-001437-16<br />Sponsor Protocol Number: CFTY720D2319<br />Sponsor Name: Novartis Pharma Services AG<br />Start Date: 2012-09-19<br />Medical condition: multiple sclerosis<br />Disease: <br />Version: 15.0<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10063399<br />Term: Relapsing-remitting multiple sclerosis<br />Level: PT<br /><br />Population Age: Adults<br />Gender: Male, Female<br />Trial Protocol: <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-001437-16/DE">DE</a> (Completed)</p>
link: 'https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2011-001437-16'
published_date: NaT
trial_source: Clinical Trials Register Europe
relevant: 
options:
  unlisted: false
---
<p>EudraCT Number: 2011-001437-16<br />Sponsor Protocol Number: CFTY720D2319<br />Sponsor Name: Novartis Pharma Services AG<br />Start Date: 2012-09-19<br />Medical condition: multiple sclerosis<br />Disease: <br />Version: 15.0<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10063399<br />Term: Relapsing-remitting multiple sclerosis<br />Level: PT<br /><br />Population Age: Adults<br />Gender: Male, Female<br />Trial Protocol: <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-001437-16/DE">DE</a> (Completed)</p>